Zervimesine fumarate

N/A

Report date: 2025/05/20 15:34:28
NME

Base Information

Drug NameZervimesine fumarate
Drug Alias NameElaytaSV-119CT-1812
ClassificationNatural product/ExtractSmall molecules > Heterocyclic drugs
Mechanisms of ActionBeta amyloid A4 protein inhibitorsMembrane-associated progesterone receptor component 1 antagonistsSigma-2 receptor modulators
TargetsMembrane-associated progesterone receptor component 1Beta amyloid A4 proteinSigma-2 receptor
Therapy Area/IndicationsCognition DisordersMacular DegenerationAlzheimer Disease +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaUnited StatesNetherlands +[5] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCogrx
China Registration ClassN/A

Develop Information

Active CompaniesCognition Therapeutics Llc
Inactive CompaniesN/A
Active IndicationsAlzheimer DiseaseLewy Body Disease
Inactive IndicationsCognition DisordersMacular Degeneration

Other Information

ATC CodeN/A
Related LinksN/A